


PATENT APPLICATION
Atty. Ref. No. 050185

1643
FFA



FIRST CLASS MAIL MAILING LABEL

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, under 37 C.F.R. 101.11 on the date indicated below and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

May 8, 2007

Date

Jeanne Guerna
Buchanan Ingersoll & Rooney PC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Uwe Karsten
Filed : June 29, 2000
Application No. : 09/606,910
Group Art Unit : 1643
Confirmation No. : 7839
Examiner : Rawlings, Stephen L.
Title : Tumor Vaccines for MUC1-Positive Carcinomas

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RESPONSE TO NOTICE TO COMPLY

Sir:

In response to the Notice to Comply with Sequence Requirements mailed on May 1, 2007, the following items are enclosed:

1. A revised paper copy of the sequence listing;
2. A revised copy of the sequence listing on diskette;

3. A statement that the paper copy and electronic copy of the sequence listing are identical.

Please amend the application to replace the current sequence listing with the sequence listing that is enclosed. This sequence listing includes no new matter.

This paper is believed timely without the need for an extension of time. If an extension of time is necessary to make the paper timely, kindly grant an extension of time and deduct the fee for same from Deposit Account No. 02-4800 in the name of Buchanan Ingersoll PC.

Entry of this amendment as well as prompt and favorable reconsideration of the pending claims are requested.

Respectfully submitted,



Dated: May 8, 2007

Duane A. Stewart III
Registration No. 54,468
BUCHANAN INGERSOLL & ROONEY PC
One Oxford Centre
301 Grant Street
Pittsburgh, Pennsylvania 15219
ph: (412) 562-1622
fx: (412) 562-1041

Notice to Comply

Application No.	Applicant(s)	
09/606,910	KARSTEN ET AL.	
Examiner	Art Unit	
Stephen L. Rawlings, Ph.D.	1643	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY